{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T07:11:14Z","timestamp":1691219474794},"reference-count":12,"publisher":"Scientific Scholar","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Natl Med J India"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/0970-258x.295954","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T20:31:06Z","timestamp":1600893066000},"page":"296","source":"Crossref","is-referenced-by-count":0,"title":["Can we stop imatinib?"],"prefix":"10.25259","volume":"32","author":[{"given":"Lalit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0970-258X.295954-1","first-page":"2851","volume-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0970-258X.295954-2","first-page":"64","volume-title":"Chronic myeloid leukemia in India","author":"Ganesan","year":"2017","journal-title":"J Glob Oncol"},{"key":"key-10.4103\/0970-258X.295954-3","first-page":"1638","volume-title":"The concept of treatment-free remission in chronic myeloid leukemia","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"key":"key-10.4103\/0970-258X.295954-4","first-page":"316","volume-title":"Chronic myeloid leukaemia: A paradigm shift in management","author":"Dasgupta","year":"2014","journal-title":"Natl Med J India"},{"key":"key-10.4103\/0970-258X.295954-5","first-page":"910","volume-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"key-10.4103\/0970-258X.295954-6","first-page":"515","volume-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"key-10.4103\/0970-258X.295954-7","first-page":"424","volume-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0970-258X.295954-8","first-page":"717","volume-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"key-10.4103\/0970-258X.295954-9","first-page":"4554","volume-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0970-258X.295954-10","unstructured":"Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase. Available at www.ash.confex.com\/ash\/2016\/webprogram\/ Paper92599.html (accessed on 25 Mar 2017)."},{"key":"key-10.4103\/0970-258X.295954-11","first-page":"1055","volume-title":"Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia.A patient-based survey on 1133 patients","author":"Breccia","year":"2015","journal-title":"Leuk Res"},{"key":"key-10.4103\/0970-258X.295954-12","first-page":"17","volume-title":"Moving treatment-free remission into mainstream clinical practice in CML","author":"Hughes","year":"2016","journal-title":"Blood"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:57:25Z","timestamp":1691218645000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/can-we-stop-imatinib\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"alternative-id":["295954"],"URL":"https:\/\/doi.org\/10.4103\/0970-258x.295954","relation":{},"ISSN":["0970-258X"],"issn-type":[{"value":"0970-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}